|1. Duc Khai Corp.|
Category: Electrical Goods
City: Ho Chi Minh
|2. Vinasun Corporation|
City: Ho Chi Minh
|3. Vinh Hiep Co., LTD.|
City: Pleiku City, Gia Lai Province
|4. Binh An Seafoods JSC.|
Category: Food Manufacturing
City: Can Tho
|5. Khiem Thanh Co., LTD.|
City: An Giang Province
|6. FAHASA Corp.|
City: Ho Chi Minh
The U.S. Food and Drug Administration (FDA) said Monday that it has approved the cancer drug Afinitor (everolimus) to treat patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis ( TS), a rare genetic disorder. This approval was for treatments of SEGA that can not be treated with surgery.
Illustration photo. Photo: Internet
TS causes benign (non-cancerous) tumors to grow in the brain and in other parts of the body including the eyes, lungs, liver, heart, skin and kidneys. TS occurs as a result of genetic mutations that lead to the development of tumors and results in a variety of possible symptoms including learning and developmental disabilities, skin abnormalities, seizures, and lung and kidney disease.
SEGAs are considered a major diagnostic feature of TS and are slow growing tumors, seen in six percent to nine percent of patients. The disease can be fatal for patients who develop complications with tumor growth on the brain. Surgery is used to remove the tumor growths in some patients.
"Patients with this disease currently have limited treatment options beyond surgical intervention," said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research "It is important for research to continue in rare diseases where patients have few or no existing drug treatment options."
Afinitor was first approved in March 2009 to treat kidney cancer. It is marketed by East Hanover, N.J.-based Novartis.
A single study of 28 patients was used to evaluate the safety and effectiveness of Afinitor to treat SEGA. At six months into the study, nine patients (32 percent) had a greater than 50 percent reduction in space the tumor occupied (tumor volume) of their largest SEGA tumor lesion. The length of time from when a patient's tumor visibly shrank and then remained stable (duration of response) for these nine patients ranged from about three months to two and one-half years with a median of 266 days. Seven of these patients retained the greater than 50 percent reduction in space the tumor occupied at time of last follow up.
Patients participating in the study did not develop any new tumors. However, no tumor resolved completely. Four of the patients on this study had previous surgery, but their tumor grew back. After receiving Afinitor, three of these patients experienced greater than 50 percent reduction in tumor volume.
In patients treated with Afinitor for SEGA, the most commonly reported side effects included upper respiratory tract infections, sinus and ear infections, mouth sores, and fever. Common laboratory test abnormalities included liver enzyme elevations, high blood cholesterol and triglycerides (hyperlipidemia), high blood sugar, and decreases in white blood cells, red blood cells ( anemia), and platelets. In patients with kidney cancer (renal cell carcinoma), lung inflammation (pneumonitis) and decreases in kidney (renal) function also have been reported.
|< Prev||Next >|
» FDA approves first companion diagnostic test for cancer drug
» Vietnam mulls suspending breast cancer drug
» Doctors warn on anti-cancer drugs
Latest Category Posts
- Death toll from tornado hitting U.S. Oklahoma city rises to 37
- Obama says IRS targeting of conservative groups 'intolerable'
- Associated Press condemns US telephone record seizure
- Venezuela launches massive street security operation
- Turkey detains 9, alleges Syrian link to car bombings
- Kermit Gosnell guilty of three murders in late-term abortions
- At least 17 injured in Mother's Day shooting in U.S.
- US government orders removal of Defcad 3D-gun designs
- Tamerlan Tsarnaev's secret Virginia burial upsets locals
- Cubans march against homophobia in Havana
Random Category Picks
Popular Category Posts
- Many questions, few answers await Obama on Mideast visit
- US porn filmmaker sued over condom rule
- Nevada military depot mortar explosion kills 7 U.S. Marines
- Fight for gay marriage goes to US Supreme Court
- Teaching and learning Vietnamese in the US
- U.S. FDA approves new multiple sclerosis treatment
- Source: Obama to appoint first female director of Secret Service
- Texas fertilizer plant explosion leaves injured
- Online news 'clipper' loses US copyright case
- 14 bodies recovered after Texas blast
- John Brennan confirmed as CIA director
- Obama to meet South Korea's Park Geun-hye in May
- Colorado prisons chief Tom Clements shot dead
- US police officer shot dead on MIT campus
- An inch of rain threatens to bring more big problems to the heartland
- Two teens convicted in US rape case
- Wave of prawn deaths baffles Chile city of Coronel
- Colorado introduces landmark gun laws
- Guatemala ex-ruler Rios Montt on trial for genocide
- Pablo Neruda: Chile exhumes poet's body in murder probe